💊 USFDA Nod Boosts $APLLTD 's US Growth

Alembic Pharmaceuticals has secured final USFDA approval for its Prucalopride Tablets (1 mg & 2 mg), a generic version of Takeda’s Motegrity, used to treat chronic idiopathic constipation (CIC) in adults. 📌 Addressable market: US$100 million (IQVIA, MAT March 2026) 📌 Total USFDA ANDA approvals: 245 (225 final + 20 tentative) Another approval strengthens Alembic’s presence in the US generics market.